Want to see UPB full AI Analyst Report?
UPB Stock Chart & Stats
$30.30
$0.36(1.20%)
At close: 4:00 PM EST
$30.30
$0.36(1.20%)
Day’s Range― - ―
52-Week Range$5.85 - $33.68
Previous CloseN/A
Volume30.66K
Average Volume (3M)593.72K
Market Cap
$348.83M
Enterprise Value$195.53
Total Cash (Recent Filing)$294.58M
Total Debt (Recent Filing)$1.11M
Price to Earnings (P/E)―
Beta1.13
Next Earnings
Aug 12, 2026EPS Estimate
-0.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.91
Shares Outstanding54,419,987
10 Day Avg. Volume435,347
30 Day Avg. Volume593,717
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)4.30
Price to Sales (P/S)512.30
P/FCF Ratio-10.97
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$42.33Price Target Upside39.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-2.87
Revenue Forecast (FY)$2.18M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthExtremely low leverage and a large equity base provide durable financial flexibility for a clinical-stage biotech. This balance sheet allows the company to fund R&D and clinical programs without near-term solvency pressure, reducing refinancing risk over the next several quarters.
High Gross MarginA roughly 66% gross margin indicates favorable unit economics typical of biologics and supports attractive long-term profitability if candidates reach commercialization. Strong product-level margins give scope to cover fixed R&D and SG&A as revenue scales over time.
Governance ContinuityRe-election of board nominees and ratification of PwC reinforce stable corporate governance and independent oversight. Continuity in leadership and auditor reduces execution and reporting risk, supporting consistent clinical and corporate decision-making over multiple years.
Bears Say
Accelerating Cash BurnSignificantly negative and worsening operating and free cash flow materially shortens runway for a clinical-stage company. Continued cash burn will likely force financing choices (dilution or debt) and constrain sustained investment in trials absent a clear revenue inflection or capital raise.
Deep Losses And Deteriorating MarginsLarge and persistent operating and net losses, together with worsening margins, indicate the business is not yet near self-sustaining profitability. This structural loss profile undermines returns on equity and heightens reliance on external capital until product revenue materializes.
Small Revenue BaseWhile revenue growth exists, the absolute revenue base remains small, limiting internal cash generation and the ability to fund clinical programs. Reliance on modest revenue leaves the company exposed to financing cycles until revenue scales meaningfully.
Upstream Bio, Inc. News
UPB FAQ
What was Upstream Bio, Inc.’s price range in the past 12 months?
Upstream Bio, Inc. lowest stock price was $5.85 and its highest was $33.68 in the past 12 months.
What is Upstream Bio, Inc.’s market cap?
Upstream Bio, Inc.’s market cap is $348.83M.
When is Upstream Bio, Inc.’s upcoming earnings report date?
Upstream Bio, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 17 days.
How were Upstream Bio, Inc.’s earnings last quarter?
Upstream Bio, Inc. released its earnings results on May 13, 2026. The company reported -$0.75 earnings per share for the quarter, missing the consensus estimate of -$0.73 by -$0.02.
Is Upstream Bio, Inc. overvalued?
According to Wall Street analysts Upstream Bio, Inc.’s price is currently Undervalued.
Does Upstream Bio, Inc. pay dividends?
Upstream Bio, Inc. does not currently pay dividends.
What is Upstream Bio, Inc.’s EPS estimate?
Upstream Bio, Inc.’s EPS estimate is -0.74.
How many shares outstanding does Upstream Bio, Inc. have?
Upstream Bio, Inc. has 54,419,987 shares outstanding.
What happened to Upstream Bio, Inc.’s price movement after its last earnings report?
Upstream Bio, Inc. reported an EPS of -$0.75 in its last earnings report, missing expectations of -$0.73. Following the earnings report the stock price went up 4.581%.
Which hedge fund is a major shareholder of Upstream Bio, Inc.?
Currently, no hedge funds are holding shares in UPB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Upstream Bio, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$42.33 (39.71% Upside)
$42.33 (39.71% Upside)
Blogger Sentiment
Bullish
UPB Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $25.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.49%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-30.28%
Trailing 12-Months
Company Description
Upstream Bio, Inc.
Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor. Beyond this, the company is actively developing treatments for severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Established in 2021, Upstream Bio maintains its operational base in Waltham, Massachusetts.
UPB Stock 12 Month Forecast
Average Price Target
$42.33
▲(39.71% Upside)
Technical Analysis
Theravance Biopharma
―
Bicycle Therapeutics
―
Prime Medicine, Inc.
―
Bicara Therapeutics Inc.
―
Zenas BioPharma, Inc.
―
Ownership Overview
8.69% Insiders
21.75% Mutual Funds
0.13% Other Institutional Investors
60.50% Public Companies and
Individual Investors